Propanc Biopharma, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2022, compared with fiscal 2021. Although the request metadata refers to “2021 Q4,” this filing reports the year ended June 30, 2022. The financial statements are audited and prepared under U.S. GAAP.
Business context
Propanc is a pre-revenue biopharmaceutical company developing PRP, an intravenous pancreatic proenzyme formulation intended to treat solid tumors and reduce recurrence and metastasis. PRP remained preclinical at year-end; the company has not established that it is safe or effective in controlled clinical trials. The company also conducts POP1 research into recombinant versions of the proenzymes. The FDA has granted PRP orphan drug designation for pancreatic cancer; its request for ovarian-cancer designation was denied.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1.991 million | $1.812 million |
| Operating loss | $1.991 million | $1.812 million |
| Interest expense | $569,000 | $449,000 |
| Net loss | $2.658 million | $2.026 million |
| Net cash used in operations | $1.436 million | $1.145 million |
| Cash at year-end | $4,067 | $2,255 |
- Administration expense rose to $1.706 million from $1.553 million; R&D expense increased to $256,000 from $231,000. With no revenue, gross margin and revenue-based margins are not applicable.
- Financing activities provided $1.491 million, mainly from convertible notes ($766,500), warrant exercises ($625,001), and common-stock sales ($99,285). Operating cash use exceeded available cash, and year-end cash was minimal.
- Current liabilities were $3.063 million, including net convertible debt of $984,260, accounts payable and accrued expenses of $1.409 million, and employee-benefit liabilities of $415,799. Total liabilities were $3.105 million; working-capital deficit was $3.048 million. Stockholders’ deficit was $3.024 million.
- The company reported approximately $144,000 of principal and $34,000 of accrued interest on two past-due convertible notes in default. Convertible financing includes variable-price conversion terms, premiums, and potential penalties.
Changes, outlook, and risks
- Net loss increased approximately 31% year over year. Higher administration costs, interest expense, derivative revaluation losses, and foreign-currency losses contributed. The prior-year period included debt-settlement gains that did not recur.
- Management planned to submit a clinical trial application for PRP in 2023 and, subject to regulatory approval and financing, start a Phase Ib first-in-human study in advanced solid-tumor patients in the second half of 2023. The filing estimated Phase Ib costs at approximately $6.5 million and projected roughly three to four years to reach a Phase IIa proof-of-concept milestone. These are plans, not assured outcomes.
- The independent auditor issued an unqualified opinion on the financial statements but included a going-concern qualification. Management and the auditor cited substantial doubt about the company’s ability to continue as a going concern; the company said it lacked resources to meet obligations for the next 12 months without additional financing. Some convertible debt was past maturity, and the financial statements contain no adjustments for the uncertainty.
- Management concluded disclosure controls and internal control over financial reporting were ineffective as of June 30, 2022, citing material weaknesses including inadequate written procedures, insufficient segregation of duties, no audit committee, and inadequate financial-reporting review. Remediation depends partly on obtaining capital.
- Potential dilution is substantial: authorized common shares increased from 1 billion to 3 billion effective July 6, 2022; lender share-reserve requirements totaled 730.2 million shares at year-end. The filing reports 677.2 million common shares outstanding on September 26, 2022, following substantial debt conversions and warrant exercises.
- Post-year-end financing included additional convertible notes. A $5 million equity-line commitment is conditional, including on an effective resale registration statement, and shares are priced at a discount to recent trading prices. Financing availability, conversion terms, and dilution remain important risks.
- PRP’s supporting human evidence described in the filing is from a 46-patient study of a rectal suppository formulation, not a controlled trial of the planned intravenous PRP product. The company’s favorable efficacy and safety statements are preliminary and require clinical confirmation. Development also depends on regulatory approvals, manufacturing, third parties, and adequate funding.
- The filing reports no litigation believed to have a material adverse effect. It discloses an IRS penalty of $30,000 plus accrued interest for late historical Form 5471 filings; the amount is included in accrued expenses. The company leases its office from a related party connected to its CEO.
Important facts for investors to verify
- Current cash, near-term obligations, past-due debt, lender maturity extensions, and the amount and terms of financing actually secured after the filing date.
- Updated shares outstanding, shares issuable upon debt conversion, warrant and lender reserves, equity-line availability, and resulting dilution.
- Regulatory status and actual timing and funding for the PRP clinical-trial application and Phase Ib study.
- Whether PRP’s preclinical findings and historical suppository data translate to the planned intravenous product and demonstrate safety or efficacy in controlled trials.
- Progress in remediating the disclosed material weaknesses and any subsequent changes in financial controls or reporting reliability.